Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
91.36
(
0.00%
)
Bitcoin
73,441.89
(
0.10%
)
News Focus
News Focus
Post# of 257660
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123038
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 218220

Tuesday, 04/03/2018 10:35:33 AM

Tuesday, April 03, 2018 10:35:33 AM

Post# of 257660

SLS—[re items #5 and #1 in your list]—…this is a GALE drug and a GALE trial.

Indeed. SLS is focused on the WT1 approach to immunotherapy, and yesterday’s PR seems designed to elicit licensing interest in the NeuVax (legacy-GALE) program. This presumably explains the unblinding of the trial based on a subgroup analysis.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today